Anxiolytics

Name: Anxiolytics
Brand: Birkhauser Verlag AG
SKU: 9783764360320
Price: 106.17 EUR
Availability: InStock

Autor: Mike Briley, David Nutt

Jazyk:

Väzba: Pevná

Vydavateľ: Birkhauser Verlag AG

Dostupnosť: Skladom u dodávateľa v malom množstve

Odosielame za 13-18 dní

106.17 €

For over thirty years the benzodiazepines monopolised not only the anxiolytic market but also clinic...

Informácie o knihe

Autor

Mike Briley, David Nutt

Jazyk

Angličtina

Väzba

Kniha - Pevná

Vydalo

2000

Stránok

181

EAN

9783764360320

ISBN

3764360321

Enbook ID

05289180

Vydavateľ

Birkhauser Verlag AG

Hmotnosť

1000

Rozmery

155 x 235 x 20

Kompletný popis

For over thirty years the benzodiazepines monopolised not only the anxiolytic market but also clinical and animal research in anxiety. Indeed many animal tests developed since the 1960s have been optimised for the benzodiazepines and some programmes have even screened candidates as potential anxiolytics on their benzodiazepine-like side-effects rather than their anxiolytic activity. With the realisation of the drawbacks of the benzodiazepines, namely their potential for tolerance and dependency, there has been a renewed interest in alternative anxiolytics both from existing drugs such as the tricyclic and monoamine oxidase antidepressants and from newer agents such as buspirone. In addition anxiety is no longer considered to be a unique entity but rather an umbrella term for a series of specific anxiety disorders such as panic disorder without or with agoraphobia, generalised anxiety disorder (GAD), specific phobias, social phobias and post-traumatic stress disorder (PTSD). These new clinical categories have opened another dimension in the therapy of anxiety requiring the optimisation of treatments for different syndromes. This book is a critical review of today's anxiolytics and those that may become the anxiolytics of tomorrow. What is clear is that currently there are few clinically satisfactory alternatives to the benzodiazepines for the treatment of acute anxiety. For chronic anxiety, it is generally agreed that benzodi azepines are not the treatment of first choice. The tricyclic and monoamine oxidase antidepressants, the serotonin reuptake inhibitors and buspirone offer better solutions for chronic anxiety but they are still far from being ideal.

Mohlo by vás zaujímať

Zákazníci, ktorí si kúpili túto knihu, kúpili tiež

Najčastejšie vyhľadávané

Categories

Authors

Publishers

Produkty

Produkty

Najčastejšie vyhľadávané

Categories

Authors

Publishers

Produkty

Produkty

Anxiolytics

Informácie o knihe

Kompletný popis

Mohlo by vás zaujímať

Zákazníci, ktorí si kúpili túto knihu, kúpili tiež